Articles from PHIL Inc.
Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI™, the first and only dual-agent prescription eye drop FDA-approved for the treatment of presbyopia.
By PHIL Inc. · Via Business Wire · April 2, 2026

Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform.
By Phil Inc. · Via Business Wire · July 6, 2023

Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with Teva Pharmaceuticals that will make Digihaler® products available for prescription using the PhilRx Patient Access Platform. Teva’s Digihaler system is the first and only smart inhaler system that can provide objective inhaler data to help patients and their doctors have informed treatment discussion in support of asthma management.
By Phil Inc. · Via Business Wire · June 6, 2023

Phil Inc., a patient access platform company that revolutionizes life science product commercialization with technology to improve patient prescription access, today announced an exclusive partnership with Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization. Through the strategic partnership, Phil will serve as Syneos Health’s hub partner, creating an end-to-end commercialization solution for life sciences organizations to ensure patients can seamlessly start and adhere to therapy and receive and refill medicines quickly, easily and affordably.
By Phil Inc. · Via Business Wire · October 25, 2022